Sign inCreate account

Report workspace tools

NCT01349920COMPLETEDanonymous

An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)

Sponsor

Source record

Merck Sharp & Dohme LLC

Phase

Source record

Not classified

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Infliximab

Indication / condition

AI-normalized

Crohn Disease

Intervention

Source record

Infliximab

Source & freshness

Source record

NCT ID

NCT01349920

Original source

ClinicalTrials.gov

Source last updated

Oct 15, 2018

Ingested at

May 22, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01349920

Title

An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)

Sponsor

Merck Sharp & Dohme LLC

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Crohn Disease

Condition normalized

Crohn Disease

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Infliximab

Target normalized

Infliximab

Interventions

Infliximab

Public preview

Source record

This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01349920

Status

COMPLETED

Phase

N/A

Sponsor

Merck Sharp & Dohme LLC

Executive brief

Investment-Ready Snapshot

This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 15, 2018
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01349920

Indication

Crohn Disease

Modality

monoclonal antibody

Target

Infliximab

Intervention

Infliximab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.